Skip to main content

Table 1 Baseline clinical characteristics of patients with T2DM and their matched non-diabetic controls separately for each ethnic group

From: Prevalence and incidence of complications at diagnosis of T2DM and during follow-up by BMI and ethnicity: a matched case–control analysis

 

White European (296,288)

African-Caribbean (16,958)

South Asian (28,380)

Overall n (341,626)

T2DM

Control

T2DM

Control

T2DM

Control

T2DM

Control

Patientsa

60,233 (20)

236,055 (80)

3425 (20)

13,533 (80)

5778 (20)

22,602 (80)

69,436 (20)

272,190 (80)

Age at index (years)b

58 (58.2, 58.4)

58 (58.3, 58.4)

49 (48.2, 49.0)

49 (48.4, 48.8)

47 (46.3, 46.9)

47 (46.4, 46.7)

57 (56.8, 57.0)

57 (56.8, 56.9)

Age groupsa

 18–40

4530 (8)

17,912 (8)

744 (22)

2932 (22)

1707 (30)

6685 (30)

6981 (10)

27,529 (10)

 41–50

11,297 (19)

44,306 (19)

1278 (37)

5063 (37)

2097 (36)

8196 (36)

14,672 (21)

57,565 (21)

 51–60

16,552 (28)

65,033 (28)

843 (25)

3326 (25)

1217 (21)

4767 (21)

18,612 (27)

73,126 (27)

 61–70

17,010 (28)

66,485 (28)

415 (12)

1641 (12)

559 (10)

2185 (10)

17,984 (26)

70,311 (26)

 71+

10,844 (18)

42,319 (18)

145 (4)

571 (4)

198 (3)

769 (3)

11,187 (16)

43,659 (16)

Malea

34,342 (57)

134,630 (57)

1778 (52)

7040 (52)

3232 (56)

1,2631 (56)

39,352 (57)

154,301 (57)

Current smokersa

12,830 (21)

46,926 (20)

449 (13)

1984 (15)

820 (14)

2839 (13)

14,099 (20)

51,749 (19)

Ex-smokersa

23,196 (39)

80,860 (34)

614 (18)

2066 (15)

756 (13)

2605 (12)

24,566 (35)

85,531 (31)

Deprivation status

 Highest affluencea

12,856 (21)

41,726 (18)

833 (24)

3548 (26)

1483 (26)

5586 (25)

15,172 (22)

50,860 (19)

 Lowest affluencea

2500 (4)

11,462 (5)

457 (13)

1595 (12)

518 (9)

1989 (9)

3475 (5)

15,046 (6)

HbA1c (%),bd

8.2 (8.2, 8.2)

 

9.1 (9.0, 9.2)

 

8.5 (8.4, 8.6)

 

8.3 (8.3, 8.3)

 

Weight (kg)b

92.9 (92.8, 93.1)

78.7 (78.5, 78.8)

88.7 (87.9, 89.4)

81.6 (81.0, 82.1)

79.2 (78.7, 79.8)

72.2 (71.8, 72.5)

91.7 (91.5, 91.9)

78.3 (78.2, 78.4)

BMI (kg/m2)b

32.6 (32.6, 32.7)

27.8 (27.8, 27.8)

31.5 (31.3, 31.7)

28.2 (28.1, 28.2)

29.6 (29.5, 29.8)

26.3 (26.3, 26.4)

32.3 (32.3, 32.4)

27.7 (27.7, 27.7)

Normal weighta

4242 (7)

29,128 (12)

359 (11)

1174 (9)

360 (6)

1517 (7)

4961 (7)

31,819 (12)

Overweighta

14,446 (24)

178,671 (76)

842 (25)

10,611 (78)

1505 (26)

16,750 (74)

16,793 (24)

206,032 (76)

Obesea

41,545 (69)

28,256 (12)

2224 (65)

1748 (13)

3913 (68)

4335 (19)

47,682 (69)

34,339 (13)

SBP (mmHg)b

140 (139.7, 140)

136 (135.6, 135.8)

136 (135.7, 137.2)

133 (132.3, 133.3)

132 (131.0, 132.1)

128 (127.7, 128.5)

139 (138.9, 139.2)

135 (135, 135.2)

SBP ≥ 140 mmHga

24,571 (41)

46,081 (20)

1029 (30)

1624 (12)

1302 (23)

1926 (9)

26,902 (39)

49,631 (18)

LDL (mg/dl)b

119 (118.6, 119)

122.3 (122.2, 122.3)

127 (126.4, 128.3)

128.7 (128.4, 128.9)

121 (120.3, 121.8)

123.9 (123.7, 124.1)

119 (119.2, 119.6)

122.7 (122.7, 122.8)

HDL (mg/dl)b

46 (45.6, 45.8)

55 (55.3, 55.4)

48 (47.4, 48.2)

57 (56.4, 56.6)

43 (43.1, 43.6)

51 (51.3, 51.5)

46 (45.5, 45.7)

55 (55.0,55.1)

Triglycerides (mg/dl)c

159 (121, 213)

115 (88, 159)

115 (81, 159)

82 (62, 115)

151 (115, 204)

115 (89, 168)

159 (115, 213)

115 (84, 159)

Comorbidities

18,014 (30)

46,449 (20)

382 (11)

963 (7)

647 (11)

1741 (8)

19,043 (27)

49,153 (18)

Cardio-protective drugsa

 Beta blockers

17,042 (28)

38,032 (16)

393 (12)

1041 (8)

710 (12)

1783 (8)

18,145 (26)

40,856 (15)

 Calcium blockers

13,736 (23)

27,188 (12)

694 (20)

1535 (11)

673 (12)

1283 (6)

15,103 (22)

30,006 (11)

 Statins

18,971 (32)

33,604 (14)

620 (18)

794 (6)

1205 (21)

1618 (7)

20,796 (30)

36,016 (13)

 ACE inhibitors

16,165 (27)

27,922 (12)

532 (16)

857 (6)

793 (14)

1290 (6)

17,490 (25)

30,069 (11)

Follow-upc

7.0 (4, 11)

8.0 (4, 11)

7.0 (4, 10)

7.0 (4, 10)

6.0 (3, 10)

7.0 (4, 10)

7.0 (4, 11)

7.0 (4, 11)

  1. ACE angiotensin-converting enzyme; SBP systolic blood pressure; DBP diastolic blood pressure; LDL low-density lipoprotein cholesterol; HDL high-density lipoprotein cholesterol; Comorbidities pre-existing cardiovascular (myocardial infarction, stroke, heart failure, angina, or coronary heart disease) or non-cardiovascular disease (renal diseases including chronic kidney disease, cancer, or depression) at the time of diagnosis
  2. an (%)
  3. bMean (95% CI)
  4. cMedian (Q1, Q3)
  5. dNot presented for non-diabetic controls